Aptamer Group Reports Robust Growth and Strategic Advances in H1 2025

Aptamer Group Plc ( (GB:APTA) ) has shared an announcement.

Aptamer Group PLC has reported substantial growth and progress in its half-year trading update for the period ending December 31, 2024. Key achievements include advancements in their Optimer® binders being used as active ingredients in Unilever deodorant trials and the validation of Alzheimer’s biomarkers for diagnostic solutions in partnership with Neuro-Bio. The company has also shown promising therapeutic potential in treating fibrotic liver disease through its collaboration with AstraZeneca. Financially, Aptamer has seen its revenue double to £0.7 million compared to the previous year, with a strong sales pipeline and repeat business from top pharmaceutical companies, positioning it for sustained growth and self-sufficiency.

More about Aptamer Group Plc

Aptamer Group PLC operates in the life sciences industry, specializing in the development of Optimer® binders to drive innovation. The company’s focus is on both long-term, high-value revenue opportunities and short-term fee-for-service projects, collaborating with major entities like Unilever and AstraZeneca.

YTD Price Performance: 13.51%

Average Trading Volume: 17,943,895

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £8.35M

For detailed information about APTA stock, go to TipRanks’ Stock Analysis page.